Heart Disease

Cardiovascular·MeSH: Heart Diseases

Prevalence

5.0 / 100K

16 drugs in development·8 companies·6 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
Alginic Sodium Diester Injection	CHINA PHARMA HOLDINGS, INC. (CPHI)
pravastatin	Aptinyx Inc. (APTX)
propafenone	Mylan II B.V. (MYL)
propylgallate	CHINA PHARMA HOLDINGS, INC. (CPHI)
Propylgallate for Injection	CHINA PHARMA HOLDINGS, INC. (CPHI)

Phase 2(4)

Drug	Company
dfv890	Novartis AG (NVS)
mas825	Novartis AG (NVS)
MAS825	Novartis AG (NVS)
SGLT2 inhibitors	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(3)

Drug	Company
2 mL SunButyrate-TG	China Foods Holdings Ltd. (CFOO)
4 mL SunButyrate-TG	China Foods Holdings Ltd. (CFOO)
dfv890	Novartis AG (NVS)

Unknown(2)

Drug	Company
Epi+Gen CHD™	Cardio Diagnostics Holdings Inc. (CDIO)
PrecisionCHD™	Cardio Diagnostics Holdings Inc. (CDIO)

Phase 4(2)

Drug	Company
transdermal nicotine	GH Research PLC (GHRS)
varenicline	GH Research PLC (GHRS)

BioSniper tracks 16 drugs in development for Heart Disease across 8 companies.

There are 6 clinical trials targeting Heart Disease tracked by BioSniper.

The estimated prevalence of Heart Disease is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.